Office-use compounding in Washington

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

The permission is a subtraction, not a grantMedium confidence

Nothing in Washington law affirmatively authorises supplying a prescriber with non-patient-specific compounded stock. What exists is an exclusion from the definition of "manufacture", plus a quality standard: RCW 18.64.270(2) requires medicinal products compounded for patient administration or distribution to a licensed practitioner for patient use or administration to meet the standards of the United States Pharmacopeia at a minimum, and WAC 246-945-100(1) carries the same formula.

The quantity phrase belongs to a different subsectionHigh confidence

The words "small, reasonable quantities" sit in subsection (24)(b), which governs repackaging of commercially available medication. The compounding exclusion is (24)(a) and it carries no quantity limit of any kind. Searching the whole of the pharmacy chapter and the pharmacy rules returns one hit for that phrase — the repackaging limb — and none for an aggregate or percentage ceiling anywhere.This is the most likely single error about Washington, and it is the kind a competitor’s compliance officer screenshots: the sentence is a real quotation from the real statute, attached to the wrong activity.

The only quantity test lives on an undated web pageLow confidence

The Department of Health publishes guidance that pharmacists may compound in very limited quantities before receiving a valid prescription based on past routine prescribing patterns, and that compounding inordinate amounts relative to the practice site in anticipation of prescriptions with no historical basis is considered manufacturing. It is persuasive, not operative; the test is proportional rather than absolute; and it is narrower than the statute, dropping the statute’s reference to distribution.The page carries no publication, revision or last-reviewed date anywhere in its markup. Where guidance and statute conflict the statute governs, but expect inspector friction.

No sterile / non-sterile splitHigh confidence

One rule covers both. WAC 246-945-100(1) applies the compounding chapters of the USP to sterile and non-sterile work in a single breath, and RCW 18.64.270(2) covers non-sterile products and sterile administered products together.A drafting defect worth knowing: only two of the four incorporated USP chapters carry a version date. The other two are incorporated with no edition pinned at all.

Label legend — one exists and it is nuclear-pharmacy onlyHigh confidence

The phrase "office use" appears exactly twice in the pharmacy rules, both inside the radiopharmaceutical section, which says that in the absence of a prescription for an individual identified patient the statement "Office Use Only" should be applied. Note the verb: should, not shall. For every other drug class Washington prescribes no office-use legend at all.

RecordsHigh confidence

Two years across the board under WAC 246-945-020(1). There is no office-use-specific record and no commission notification tied to office use.

Nonresident pharmacy — the statute contradicts itselfLow confidence

RCW 18.64.360(1) makes any pharmacy outside the state that ships, mails or delivers legend drugs into it a nonresident pharmacy that must be licensed. Subsection (7) then says the licence requirements of that section apply to nonresident pharmacies that ship into the state only under a prescription. Read naturally, (7) limits the trigger to prescription shipments and leaves non-patient-specific stock outside the nonresident pharmacy licence entirely — which pushes it toward the wholesaler licence instead.The two subsections are in genuine tension and no source resolves them. This page flags it rather than picking a side. Separately, every nonresident pharmacy shipping in must designate a resident agent in Washington for service of process.

Last changeHigh confidence

The compounding rule was last amended effective 16 May 2024, pinning two USP chapters, and it was untouched in 2025 and 2026 — the rule appears in neither year’s register tables, so no compounding rulemaking was opened, proposed or adopted in either. A 2025 policy rescission means the USP chapters now bind by rule rather than by policy.One office-use-adjacent project is dead rather than pending: the commission’s alternate distribution models rulemaking had both its proposal and its inquiry withdrawn in 2026, because the legislature barred the commission from implementing any new or amended rules on alternative distribution models until it grants direction and funds implementation. That bar sunsets on 30 June 2027.

Washington at a glance

Receiving 503B office stock in Washington

Washington is the clearest state in this family on the receiving side, and the only one that answers the ownership question in terms. An outsourcing facility licenses here as a wholesaler, because no outsourcing-facility category exists; a private practice sits outside the licensing scheme altogether, by name.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Washington asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inHigh confidence

A wholesaler licence from the pharmacy commission. WAC 246-945-246(1) requires every wholesaler engaged in wholesale distribution into, out of or within the state to be licensed, and paragraph (e) names outsourcing facilities required to be registered with FDA that are located in Washington or that distribute or sell drugs into Washington. There is no outsourcing-facility licence in Washington — the phrase appears in two rule sections and no statute. An out-of-state applicant must also supply a site inspection report from its home-state regulator or a recognised third party from within the last two years, and again every two years at renewal.Do not publish a fee: no outsourcing-facility line exists in the fee schedule and no Washington document states which one applies. There is also an operational gap worth knowing — the department names these facilities as a wholesaler application type on its website while the application form itself has no box for them. The rule compels the licence; the form gives no way to declare it.

Does your practice need a permit?High confidence

No, and Washington says so in terms. RCW 18.64.011(16) excludes an individual practitioner’s office and a multipractitioner clinic from "health care entity" — "regardless of ownership, unless the owner elects licensure as a health care entity." Solo and group practices are both outside it, the ownership question is foreclosed in both directions, and the licence is a voluntary opt-in. An unlicensed private office also sits outside the whole facility-standards part of the rules, which applies to pharmacies, health care entities and hospital pharmacy associated clinics.Electing the licence is probably counterproductive: it imports a pharmacist the practice does not otherwise need, because receipt, administration, dispensing and delivery by a health care entity must be performed under the supervision or at the direction of a pharmacist, with a designated responsible pharmacy manager and a separate licence for each location. This is the one state in the family where the entity question has a published answer, and the answer is that ownership is irrelevant.

Administer vs dispenseMedium confidence

Authority to possess flows from the practitioner’s own licence: the legend-drug prohibition does not apply to a practitioner acting within the scope of their licence. Dispensing directly to an ultimate user is permitted without a prescription but carries a labelling duty — prescriber name, complete directions, drug name and strength per unit dose, patient name and date — and violating it is a misdemeanor. There is no dispensing-practitioner registration in Washington; the duty is a labelling one.Two citation traps here. RCW 18.64.250 is captioned as though it contains exceptions and its body is a bare list of prohibited acts — cite RCW 18.64.255 instead. And WAC 246-945-455 governs drugs that remain under a supplying pharmacy’s control, such as floor stock and emergency kits; an arm’s-length purchase where title passes to the practice is not that arrangement. The Medical Commission’s own chapter was not examined, which is why this item is not marked high.

Scheduled (controlled) stockHigh confidence

No separate Washington registration exists for prescribers. RCW 69.50.302(4) provides that personal practitioners licensed or registered in Washington under their professional licensing acts are not required to register under that chapter, and it is self-executing — no application and no fee. The other controlled-substance registrant categories in the rules cover opioid treatment programs, analytical laboratories, dog handlers and precursor-chemical agencies, and none of them describes a physician practice.

How to check a facility’s credential before you order is set out in how to place an office-use order.

What this page does not establish

• Whether routine office-use supply to practitioners triggers Washington wholesaler licensure is the single biggest open question about this state, and no primary source resolves it. Office stock is not dispensed pursuant to a prescription, so the exclusion that covers dispensing does not reach it; the nearest exclusion is capped and limited to temporary shortages; and the statute expressly names practitioners as a wholesale customer class. The text leans one way and the industry plainly operates the other way. That the question is unanswered is the finding — treat any confident answer, in either direction, as unsourced.
• The two nonresident-pharmacy subsections contradict each other on what triggers the licence, and nothing we found resolves them.
• The rule that captures outsourcing facilities is under open rulemaking: an inquiry filed in May 2026 reopens the wholesaler and manufacturer licensing rules to clarify requirements for virtual entities. Workshops had not closed when this page was written, and the filing does not mention outsourcing facilities even though the provision that captures them is in scope.
• The official Washington State Register was roughly three and a half weeks behind when this page was reviewed, so any commission filing in that window is invisible to us. Any statement here that nothing is pending in Washington has a shelf life measured in days rather than months.
• The one rule imposing an obligation specific to outsourcing facilities requires compliance with a "FDA guidance document" and names no title, date, number or link. It is unenforceable as written, and we cannot tell you what it requires.
• The Medical Commission’s own chapter and the statute governing physicians are unexamined here, so the finding that Washington has no dispensing-practitioner registration is a reading of the pharmacy law alone. The wholesaler fee for an outsourcing facility is an inference; no Washington document states it.